DMSO Has Not Been Shown to Reverse Spinal Cord Paralysis in Humans

DMSO has not been shown to reverse paralysis caused by spinal cord injury in humans. Some animal studies suggest a possible benefit when treatment is given soon after injury, but those findings do not establish that a DMSO lotion, oral product or infusion restores human spinal cord function. Recovery testimonials do not fill that gap.

New paralysis, weakness or loss of sensation after an injury needs emergency medical care—not a trial of DMSO. Prompt assessment, spinal stabilization and, where indicated, surgery can help prevent further damage. NINDS describes these immediate treatments.

What the paralysis stories actually show

The article “Jackson’s Massive Miracle & DMSO’s Role In Reversing Paralysis” presents a hockey player’s recovery narrative alongside other testimonials and animal experiments. It makes strong claims about preventing or reversing paralysis, yet also states: “As far as I know, no formal studies on DMSO after spinal injuries have been conducted in humans.”

A recovery story can describe meaningful improvement without establishing what caused it. To evaluate DMSO’s contribution, readers would need documented injury severity, neurological examinations before and after treatment, the treatment timeline, other care received and a suitable comparison group. The blog’s narrative is not a controlled human trial.

The distinction matters because spinal cord injuries have different recovery potential. An incomplete injury preserves some communication across the injured area. NINDS also explains that an injury causing little or no nerve-cell death can allow an almost complete recovery. Improvement after starting a product is therefore not, by itself, proof that the product repaired the cord. Source: NINDS.

The animal evidence is real—but limited and mixed

A particularly relevant study, Efficacy of a Metalloproteinase Inhibitor in Spinal Cord Injured Dogs, used randomization, blinding and a saline control. It enrolled dogs with naturally occurring spinal cord injuries from disc herniation—not people with traumatic paralysis.

Study detail	What it means for the claim
Three groups: GM6001 dissolved in DMSO, DMSO alone, and saline	The design could distinguish a DMSO effect from the effect of the experimental drug.
Treatment was given by injection under the skin within 48 hours of injury	It did not test a consumer lotion, oral DMSO or treatment for years-old paralysis.
All dogs underwent surgical decompression and standardized rehabilitation	DMSO was studied alongside other care, not as a replacement for it.
The primary neurological assessment was at 42 days	This was a short-term functional outcome, not proof of permanent spinal cord regeneration.

In the severely injured subgroup, DMSO-treated dogs had better motor recovery than saline-treated dogs. Sensory and postural scores did not differ significantly between groups. In dogs with mild-to-moderate injuries, treatment group did not influence recovery. The study also reported that 17 dogs did not return for the 42-day examination. These are encouraging preclinical findings, with incomplete follow-up—not evidence that human paralysis can reliably be reversed. Source: canine trial.

Other experiments were negative. In a 15-rat study, researchers applied 10% DMSO directly to the exposed spinal cord one hour after injury. They found no significant improvement in spinal cord blood flow or evoked electrical responses compared with saline. This was not ordinary skin application.

A veterinary review likewise describes both positive and negative DMSO findings and calls for further investigation in dogs. These results offer grounds for research—not a reason to copy animal treatment protocols for people.

Approval and safety do not support self-treatment

In the United States, prescription RIMSO-50 is a 50% DMSO solution placed directly into the bladder for symptomatic relief of interstitial cystitis. Its prescribing label, revised March 2021, states that it has not been approved as safe and effective for any other indication and explicitly says it is not for intravenous or intramuscular injection. Bladder-use approval does not establish a spinal cord treatment benefit. Source: prescribing label.

DMSO also is not a harmless topical experiment. Memorial Sloan Kettering notes that it rapidly penetrates skin and can enhance skin penetration of other drugs. Reported adverse effects include skin irritation, gastrointestinal reactions, dizziness and low blood pressure; industrial DMSO may contain other chemicals. MSK also reports neural damage in mouse experiments, while emphasizing that its clinical relevance is unknown. That finding is a safety uncertainty—not proof that DMSO damages human spinal cords.

There is no established human paralysis regimen to recommend. A purity claim or a clinic offering DMSO infusions does not answer whether the treatment works.

A useful next step

For someone living with spinal cord paralysis, bring the specific DMSO claim to a spinal injury specialist or rehabilitation physician. Ask whether there is a controlled human study matching the injury, route of administration and proposed outcome—not merely an animal experiment or testimonial. Discuss legitimate clinical-trial options without interrupting rehabilitation or other prescribed care.

For the broader distinction between medical applications and unsupported claims, see established DMSO uses in humans.